

Jubilant expands drug discovery alliance with Janssen

21 February 2014 | News | By BioSpectrum Bureau

Jubilant expands drug discovery alliance with Janssen



Jubilant Biosys, a Bengaluru based subsidiary of Jubilant Life Sciences, announced on February 21, 2014 that it has expanded its drug discovery alliance with Janssen Pharmaceutica N.V., Beerse, Belgium. The alliance was forged initially in the year 2011 and aims to deliver preclinical candidates to Janssen.

The new agreement into multiple therapeutic areas has been expanded owing to Jubilant's diversified skill sets in various therapeutic areas. Most of the research will be undertaken at Jubilant Biosys, India and some parts at Jubilant Discovery Center, USA.

Janssen Pharmaceutica, Belgium is part of the 'Janssen Pharmaceutical Companies of Johnson & Johnson'. The collaboration between the two organizations has been expanded to leverage Jubilant's drug discovery capabilities on selected drug discovery targets to advance programs in multiple disease areas.

Jubilant will carry out research services and will deliver preclinical candidates to Janssen for potential development and commercialization. In addition to research funding, Jubilant will also receive milestones and royalties should Janssen successfully progress the assets into clinical development and commercialization.

"We are pleased to announce the expansion of the Janssen- Jubilant collaboration and look forward to discovering Novel Chemical Entities (NCE's) that address the unmet medical needs in these important disease areas", said Dr Subir K Basak,

president, Jubilant Biosys (Global Drug Discovery Services)". Over the past several years, we have been strengthening our disease franchises from a scientific perspective, and this collaboration serves as a validation of those efforts. We look forward to a long, and mutually beneficial, partnership."

Jubilant provides comprehensive drug discovery solutions from target discovery to IND in partnership with leading healthcare companies worldwide, offering integrated & collaborative drug discovery services across early discovery, synthetic and medicinal chemistry including scale up and pre-clinical services.

Jubilant houses eminent scientists who carry with them rich experience from global pharmaceutical companies and academic institutions. The company is one of the leading service providers in Protein X-Ray crystallography in India, which in combination with medicinal chemistry and computational chemistry provides a powerful Structure Based Drug Design platform and a best niche platform to build and drive Structure Activity Relationship (SAR) for various discovery programs. Jubilant has been a partner to some of the major large and mid-size pharma and Biotech companies.